Your browser doesn't support javascript.
loading
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan, Charles J; Smith, Matthew R; Fizazi, Karim; Saad, Fred; Mulders, Peter F A; Sternberg, Cora N; Miller, Kurt; Logothetis, Christopher J; Shore, Neal D; Small, Eric J; Carles, Joan; Flaig, Thomas W; Taplin, Mary-Ellen; Higano, Celestia S; de Souza, Paul; de Bono, Johann S; Griffin, Thomas W; De Porre, Peter; Yu, Margaret K; Park, Youn C; Li, Jinhui; Kheoh, Thian; Naini, Vahid; Molina, Arturo; Rathkopf, Dana E.
Afiliación
  • Ryan CJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: ryanc@medicine.ucsf.edu.
  • Smith MR; Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.
  • Fizazi K; Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
  • Saad F; University of Montréal, Montréal, Québec, Canada.
  • Mulders PF; Radboud University Medical Centre, Nijmegen, Netherlands.
  • Sternberg CN; San Camillo and Forlanini Hospitals, Rome, Italy.
  • Miller K; Charité Berlin, Berlin, Germany.
  • Logothetis CJ; MD Anderson Cancer Center, Houston, TX, USA.
  • Shore ND; Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.
  • Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Carles J; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Flaig TW; University of Colorado Cancer Center and University of Colorado School of Medicine, Aurora, CO, USA.
  • Taplin ME; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Higano CS; University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • de Souza P; University of Western Sydney School of Medicine and Ingham Institute, Liverpool, Australia.
  • de Bono JS; The Institute of Cancer Research and the Royal Marsden Hospital, Sutton, United Kingdom.
  • Griffin TW; Janssen Research & Development, Los Angeles, CA, USA.
  • De Porre P; Janssen Research & Development, Beerse, Belgium.
  • Yu MK; Janssen Research & Development, Los Angeles, CA, USA.
  • Park YC; Janssen Research & Development, Raritan, NJ, USA.
  • Li J; Janssen Research & Development, Raritan, NJ, USA.
  • Kheoh T; Janssen Research & Development, Los Angeles, CA, USA.
  • Naini V; Janssen Research & Development, Los Angeles, CA, USA.
  • Molina A; Janssen Research & Development, Menlo Park, CA, USA.
  • Rathkopf DE; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lancet Oncol ; 16(2): 152-60, 2015 Feb.
Article en En | MEDLINE | ID: mdl-25601341
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Óseas / Prednisona / Antineoplásicos Hormonales / Neoplasias de la Próstata Resistentes a la Castración / Androstenos Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Óseas / Prednisona / Antineoplásicos Hormonales / Neoplasias de la Próstata Resistentes a la Castración / Androstenos Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article